Immune-Onc Therapeutics, Inc. is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients.
--(BUSINESS WIRE)-- Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline built upon strategic collaborations and cutting-edge research from The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Its lead program, an antibody targeting LILRB4, is being developed to treat acute myeloid leukemia and other cancers. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit www.immune-onc.com.
| Company: | Immune-Onc Therapeutics, Inc. | |
| Headquarters Address: | 795 San Antonio Road | |
| Palo Alto, CA 94303 | ||
| Main Telephone: | 16504571745 | |
| Website: | ||
| Type of Organization: | Private | |
| Industry: | Biotechnology | |
| Key Executives: | CEO: Charlene Liao | |
| Public Relations | ||
| Contact: | Tara Cooper | |
| Phone: | 650-303-7306 | |
| Email: |
View source version on businesswire.com: https://www.businesswire.com/news/home/20191121005345/en/
Source: Immune-Onc Therapeutics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20191121005345/en
